Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma
Sarah Burke(Roswell Park Comprehensive Cancer Center), Andrew K.L. Goey(Roswell Park Comprehensive Cancer Center)
Cited by 9
Related Papers
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
|Clinical Cancer Research|2016|59